Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
THRIVE: Nirsevimab for RSV Prevention in Aboriginal and Torres Strait Islander Children
NCT07578298Phase 4Recruiting
- Sponsor
- Menzies School of Health Research
- Start
- Jun 2026
- Primary completion
- Jul 2030
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of nirsevimab in respiratory syncytial virus infection (RSV), sponsored by Menzies School of Health Research. Started Jun 2026; status: recruiting.
02
Drugs
nirsevimab
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT07578298.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07578298.